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Abstract: 
 
Many of the botanical “immunomodulators”, a class of herbal medicines widely recognized in 
traditional medical systems such as Chinese Medicine (TCM) and Ayurvedic Medicine, alter 
immune function and may offer clinically relevant therapeutics or leads to therapeutics. Many of 
these traditional remedies are prepared from combinations of medicinal plants which may 
influence numerous molecular pathways. These effects may differ from the sum of effects from 
the individual plants and therefore, research demonstrating the effects of the formula is crucial 
for insights into the effects of traditional remedies. In this review we surveyed the primary 
literature for research that focused on combinations of medicinal plants and effects on cytokine 
activity. The results demonstrate that many extracts of herb mixtures have effects on at least one 
cytokine. The most commonly studies cytokines were IL-4, IL-6, IL-10, TNF and IFN-γ. The 
majority of the formulas researched derived from TCM. The following formulas had activity on 
at least three cytokines; Chizukit N, CKBM, Daeganghwal-tang, Food Allergy Formula, 
Gamcho-Sasim-Tang, Hachimi-jio-gan, Herbkines, Hochuekki, Immune System Formula, Jeo-
Dang-Tang, Juzen-taiho-to, Kakkon-to, Kan jang, Mao-Bushi-Saishin-to, MSSM-002, Ninjin-
youei-to, PG201, Protec, Qing-huo-bai-du-yin, Qingfu Guanjieshu, Sambucol Active Defense, 
Seng-fu-tang, Shin-Xiao-Xiang, Tien Hsien, Thuja formula, Unkei-to, Vigconic, Wheeze-relief-
formula, Xia-Bai-San, Yangyuk-Sanhwa-Tang, Yi-fey Ruenn-hou, and Yuldahansotang. Of the 
western based combinations, formulas with Echinacea spp. were common and showed multiple 
activities. Numerous formulas demonstrated activity on both gene and protein expression. The 
research demonstrates that the reviewed botanical formulas modulate cytokine activity, although 
the bulk of the research is in vitro. Therapeutic success using these formulas may be partially due 
to their effects on cytokines. Further study of phytotherapy on cytokine related 
diseases/syndromes is necessary. 
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Article: 
 
1. Introduction 
 
Traditional herbal pharmacotherapy is well known for combining plant species that results in 
complex phytochemical mixtures in the attempts to ameliorate pathophysiological processes. 
While research is necessary on isolated constituents and single herbal extracts to provide 
information about the molecular modes of activity, such studies have limited relevance to the 
practical use of herbs due to the traditional custom of dispensing herbal medicine in formulas 
(Walker, 2006). The rationale for formulating suggest that the introduction of the complex 
mixture of chemistry into a human system provides not only pharmacologically active 
compounds, but concomitant compounds that are important to the therapeutic effect (Spelman et 
al., 2006b). Supporting this view are numerous studies that have established that 
pharmacokinetic potentiation by way of altered absorption, distribution, metabolism and 
elimination is common place after ingestion of phytochemical mixtures. 
 
Wagner (2005) points out that herbs can be advantageous in treating pathophysiology due to 
their chemical complexity. For example, an additive effect can be expected if two bioactive 
substances target the same pharmacological target, while a synergic activity commonly results if 
two or more compounds target different pharmacological sites (Wagner, 2005). Synergic effects 
have been estimated to increase activity 50–2000-fold compared to equivalent concentrations of 
a single compound (Tegos et al., 2002, Wagner, 2005). For example, rhein, an antimicrobial 
from Rheum officinale (Baill, Polygonaceae), potentiated bacterial killing up to 2000-fold when 
combined with a plant-based MDR efflux pump inhibitor (Tegos et al., 2002). 
 
Given that plants’ resistance to pests, including mammalian herbivores, has been shown to be 
due to mixtures of bioactive compounds (Dixon, 2001, Dyer et al., 2003; Firn and Jones, 2003; 
Fujita and Kubo, 2005, Mello and Silva-Filho, 2002, Thoison et al., 2004), this synergic effect is 
suggested to be the rule rather than the exception when medicinal plants interface with 
mammalian systems (Spelman et al., 2006b). Hence, phytotherapists suggest that multi-modal 
molecular activity is an integral aspect of herbal therapies and that this offers an advantage over 
isolated constituents (Spelman et al., 2006b, Wagner, 1999, Williamson, 2001). Zhu et al. (2002) 
illustrated this by demonstrating that individual herbs from a formula traditionally used for 
gastrointestinal issues failed to show the gastroprotective effect that the formula demonstrated at 
equivalent doses. 
 
Inflammatory and immune-related illnesses have a notable history of being treated with herbal 
formulas that are considered immunomodulators (Mills and Bone, 2000). Immunomodulators 
may be defined as botanical medicines that alter the activities of the immune system via the 
dynamic regulation of messenger molecules—cytokines, adhesion molecules, nitric oxide, 
hormones, neurotransmitters, and other peptides (Spelman et al., 2006a). Reviews of the primary 
literature suggests many of the immune-related effects of medicinal plants may be via cytokine 
modulation (Calixto et al., 2004, Spelman et al., 2006a). 
 
Cytokines are pleiotropic peptides and glycoproteins having multiple sources, multiple targets, 
and multiple functions. Although constitutive secretion is low to absent, virtually every nucleated 
cell type responds to injurious stimuli with cytokine secretion. Thus these compounds are critical 
to innate and adaptive inflammatory responses, as well as cell growth, differentiation, cell 
death, angiogenesis, developmental and bodily repair processes (Oppenheim, 2001). 
 
Manipulation of cytokine activity shows promise in many disease states related to immune 
function including asthma (Stirling and Chung, 2000) and cancer (Oleksowicz and Dutcher, 
1994). Considering the diverse and pleiotropic activities of cytokines, pharmacology based on 
cytokine signaling may also prove promising for disorders seemingly unrelated to immune 
function. For example, a number of cardiac diseases are associated with elevated cytokine 
expression, and can effect cardiac processes (Prabhu, 2004). Furthermore, the inflammatory 
milieu of cardiovascular disease is known to be influenced by cytokines from leukocytes, the 
liver, the heart, vessel walls, and adipose tissue (Rader, 2000). 
 
Due to the regulation of different types of immune and somatic cells, cytokines have been widely 
researched for many diseases and syndromes. As a result of such diverse and far reaching effects 
of cytokines and the frequency of use of herbal formulas that are believed to impact immune 
function, this work provides a review of the primary literature on the effects of herbal formulas. 
We suggest that modulation of cytokine activity is a partial explanation for the observed activity 
of these formulas in traditional medicine. 
 
2. Materials and methods 
 
2.1. Search strategy 
 
Titles were screened for all hits to the terms “herbs and cytokines,” “herb* formulas and 
cytokines” and “herbal* combinations and cytokines,” “medicinal plants and cytokines,” 
“Chinese Medicine and cytokines,” “Ayurvedic Medicine and cytokines,” “Ayurveda and 
cytokines.” A cutoff date of June 30, 2007 was used to keep the manuscript size manageable. 
These results were then searched with the key word “combination,” and again with a keyword of 
“formulas.” Databases utilized included Pubmed, Biosis, EBSCO and SciFinder Scholar, as well 
as a hand search through journals and bibliographies. No language restriction was observed. 
 
2.2. Criteria for inclusion 
 
The following parameters had to be met for study inclusion: firstly, investigations on 
combination of herbs were accepted. Research on isolated constituents or single herbs was 
rejected. Secondly, model types were considered; in vitro and in vivo, animal and human models 
were accepted. Thirdly, at least two of the following were required; method of preparation of the 
botanical medicine, concentration of the plant preparation and dose/exposure time. Lastly, only 
studies demonstrating statistically significant results of p < 0.05 with regards to cytokine activity 
were included. 
 
385 titles and abstracts were reviewed for inclusion criteria. 326 studies were eliminated due to 
failing inclusion criteria such as constituent based research, or statistically not significant. Fifty-
nine papers met the criteria. 
 
Table 1A. Ingredients of formulations. 
Formula name Genus species or pharmaceutical nomenclature 
Allergina Schizonepetae herba, Forsythiae fructus, Ledebouriellae radix, Angelicae radix, Cindii rhizome, Paeoniae radix alba, Angelicae 
dahuricae radix, Bupleuri radix, Aurantinii fructus, Scutellariae radix, Fructus angelicae, Platycodi radix, Glycyrrhizae 
radix, Trichosanthis radix, Taraxaci herba, Lonicerae flos 
AT2 Hirudo, Turtle shell, Panax notoginseng 
Bouum-Myunyuk-Dan Hedyotis diffusa, Astragalus membranaceus, Paeonia lactiflora, Angelica sinensis, Ophiopogon japonicus, Atractylodes 
maceocephala, Adenophora triphylla, Rehmannia glutinosa, Spatholobus suberectus, Citrus unshin, Hordeum 
vulgare, Callusgallus domesticus, Ulmus pumila, Anemarrhena asphodeloides, Phellodendron amurense, Glycyrrhizae uralensis 
CH-100 Unspecified 
Chizukit N Echinacea purpurea, Propolis, Sucrose and Orange Oil 
CKBM Panax ginseng, Schisandra chinensis, Fructus crataegi, Zizyphus jujube, Glycine max 
CPD 861 Not specified 
Daeganghwal-tang Angelicae koreanae radix, Cimicifuga rhizome, Araliae cordatae radix, Atractylodes rhizome, Sinomeni caulis et 
rhizome, Clematidis radix, Atractylodes rhizome alba, Angeliaca gigantis radix, Poria, Alismatis rhizome, Glycyrrhizae radix 
Dang-gui-bu-xue-tang Angelica sinensis, Astragalus membranaceus 
Echinacea Formula E. angustifolia radix, E. purpurea radix, E. purpurea herba, Thymus vulgaris, Mentha piperita 
Echinacea/Thuja Formula Thujae summitates, Baptisia tinctoriae radix, E. purpurea radix, E. pallidae radix 
FAHF-1 Ganoderma lucidum, Aconiti Carmichaeli Praeparata, Pruni Mume, Zanthoxyli Bungeana, Asarum europaeum, Coptis 
trifolia, Phellodendron amurense, Zingiber officinalis, Cinnamomum cassia, Panax ginseng, Angelica sinensis 
FAHF-2 Ganoderma lucidum, Fructus pruni mume, Pericarpium zanthoxyli bungeana, Rhizoma coptidis, Cortex phellodendri, Rhizoma 
zingiber officinalis, Ramulus cinnamomum cassia, Radix ginseng, Corpus radix Angelica sinensis 
Fei-shu-ling Platycodon grandiflorum, Angelica sinensis, earth worm, Raphanus sativus 
Gamcho-Sasim-Tang Glycyrrhiza uralensis, Scutellaria baicalensis, Zingiber officinale, Pinellia ternata, Panax ginseng, Coptis japonica 
Hachimi-jio-gan Rehmannia radix, Cornus fructus, Dioscorea rhizome, Alismatis rhizoma, Poria, Moutan cortex, Cinnamomum cortex, 
processed Aconitum tuber 
Herbkines Atractylodes macrocephala, Dioscorea batatas, Glycyrrhiza uralensis, Cinnamomum cassia, Rubus coreanus, Liriope 
platyphylla, Astragalus membranaceus, Cornus officinalis 
Hochuekki Astragali radix, Ginseng radix, Atractylodes rhizome, Angelicae radix, Zizyphi fructus, Aurantii nobilis pericarpium, Bupleuri 
radix, Glycyrrhizae radix, Cimicifugae rhizome, Zingiberis rhizoma 
Hwanglyun-Haedok-Tang Scutellaria baicalensis, Coptis japonica, Phellodendron amurense, Gardenia jasminoides 
Immune System Formula 
(Sambucol Active Defense) 
38% Black Elderberry, Glucose, Raspberry extract, Citric acid, Honey, Echinacea augustifolia, Echinacea 
purpurea, Propolis, Ascorbic Acid, Zinc Gluconate 
Jeo-Dang-Tang Rhei rhizome, Tabanus, Irubo, Persicae semen 
Juzen-taiho-to Astragalus membranaceus, Cinnamomum cassia, Rehmannia glutinosa, Paeonia lactiflora, Cnidium officinale, Atractylodes 
lancea, Angelica acutiloba, panax ginseng, Poria cocos, Glycyrrhiza uralensis 
Kakkon-to Puerlae radix, Ephedrae herba, Cinnamomum ramulus, Paeoniae alba radix Glycyrrhiza radix, Zingiber recens rhizome, Jujubae 
fructus, Etradix notopterygii rhizome, Angelicae pubescentis radix, Chuanxiong rhizome, Bupleuri radix 
Kan jang Andrographis paniculata, Eleutherococcus senticocus 
Formula name Genus species or pharmaceutical nomenclature 
Kanzo-bushi-to Glycyrrhizae radix, Aconitum tuber, Atractylodis lancease rhizome, Cinnamomum cortex 
Keyuling Astragalus membranaceus, Panax ginseng, Epimedium sagittatum 
Liu-Shen-Wan Moschus berezovskii, Bos taurus domesticus, Bufo Bufo gargarizans, Drybalanops aromaticua, Pteria martensii 
Mao-Bushi-Saishin-to Asarum heterotropias, Ephedra sinica stapf, Aconiti lateralis preparata 
 
Table 1B. Ingredients of formulations. 
Formula name Genus species or pharmaceutical nomenclature 
MSSM-002 Perilla frutescens, Descurainia Sophia, Prunus armeniaca, Scutellaria baicalensis, Sophora flavescens, Angelica 
sinensis, Platycodon grandiflorum, Glycyrrhiza urlensis, Zizyphus jujube, Zingiber officinale, Pteria margaritiferi, Ganoderma 
lucidum 
Nao-yi-an Not specified 
Ninjin-to Panax ginseng, Atractylodes lancea, Zingiber officinale, Glycyrrhiza uralensis 
Ninjin-youei-to Formula not specified 
PanaWang Panax ginseng, Bos Taurus, Corydalis yanhusuo, Torilis japonica, Allium sativum, Magnolia obovata, Paeonia lactiflora, Cnidium 
officinale, Cinnamomum cassia, Astragalus membranaceus 
PG201 Chaenomeles speciosa, Achyranthes bidentata, Angelica sinensis, Cnidium officinale, Gastrodia elata, Acanthopanax 
senticosus, Carthamus tinctorius, Cinnamomum aromaticum, Gentiana macrophylla, Ledebouriella sesloides, Clematic 
chinensis, Pholmis umbrosa 
Protec Echinacea purpurea, Echinacea angustifolia, Propolis, Vitamin C, Rosa canina 
QFGJS Caulis Sinomenii, Aconiti lateralis preparata, Rhizoma Curcumae longae, Radix Paeoniae alba, Cortex Moutan 
Qing-huo-bai-du-yin Astragalus membranaceus, Lonicera japonica, Scutellaria baicalensis, ophiopogon japonicus, Eriobotrya japonica 
Sambucol Black Elderberry 
Syrup 
38% Black Elderberry, Glucose, Raspberry extract, Citric acid, Honey 
Sambucol for Kids 19% Elderberry, Raspberry extract, Citric acid, Echinacea angustifolia, Echinacea purpurea, Propolis 
Sairei-to Bupleuri radix, Glycyrrhizae radix, Cinnamomi cortex, Scutellariae radix, Alismatis rhizome, Pineliae 
tuber, Poluporus, Hoelen, Atractylodislanceae rhizome, Zizyphi fructus, Ginseng radix, Zingiberis rhizome 
Seng-fu-tang Not specified 
Sesim-Tang Poria cocos, Zizyphus spinosa, Pinellia ternate, Tricticum sativum, Panax ginseng, Citrus unshiu, Aconitum carmichaeli, Acorus 
gramineus, Glycyrrhiza uralensis 
Shang Jong Shiah Tong 
Yong Tong Feng Wan 
Cortex phellodendri, Rhizoma atractylis, Rhizoma arisaematis, Lignum cocculi trilboi, Radix gentianae, Radix heraclei, Massa 
medicate fermentata, Cirtex cinnamomii, Radix clematidis, Flos carthamic, Rhizoma notopterygii, Semen persicae 
Shaur Yau Gan Tsao Tang Radix paeoniae, Radix glycyrrhizae 
Shi-bi-lin Fructus xanthii, Radix Angelicae dahuricae, Radix Gentianae, Herba Verbenae, Radix, Saposhnikovia, Flos Magnoliae 
Shi-ka-ron Ginseng radix, Lithospermi radix, Angelicae radix, Houttuyniae herba, Astragali radix, Cniddi rhizome, Coicis semen, Glycyrrhiza 
radix 
Shin + Xiao + Xiang Shin-yi-san 
Formula name Genus species or pharmaceutical nomenclature 
Magnolia lili-flora, Asarum heterotropoieds, Liquisticum sinense, Saposhnikovia divaricata schischk, Angelica 
dahurica, Liqusticum wallichi franch, Cimicifuga foetida, Akebia quinata, Glycyrrhiza uralensis 
Xiao-qing-long-tang 
Ephedra sinica stapf, Paeonia lactiflora, Asarum heterotropoides, Zingiber officinale, Glycyrrhiza uralensis, Cinnamomum 
cassia, Pinellia ternate, Schisandra chinesis 
Xiang-sha-liu-jun-zi-tang 
Panax ginseng, Atractylodes macrocephala koidz, Poria cocos, Glycyrrhiza uralensis, Citrus reticulata, Pinellia terrnata, Amomum 
xanthioides, Saussurea lappa 
Sho-saiko-to Bupluerum radix, Pinellia tuber, Scutellariae radix, Jujube fructus, Ginseng radix, Glycyrrhiza radix Zingiber rhizome 
Sho-seryu-to Ephedra rhizome, Paeoniae radix, Asarum radix, Zingiber rhizome, Glycyrrhiza radix and rhizome, Cinnamomi rhizome, Pinellia 
rhizome, Schisandra fructus 
Shu Jin Lih An Saan Radix saposhnikoviae, Radix angelicae grosseserratus, Rhizoma ligustics, Rhizoma notopterygii, Radix angelicae, Hoelen, Radix 
achyranthis, Radix glycyrrhizae, Radix rehmanniae Rhizoma atractylodis, Radix paeoniae, Flos carthami, Semen 
persicae, Rhizoma arisaematis, Exocarpium citri sinensis, Fructus chanomelis speciosae, Radix simomenii Radix 
clematidis, Fructus forsythiae, Lignum mutang, Radix scutellariae, Radix gentianae, Radix aconite, Caulis bambusae 
 
Table 1C. Ingredients of formulations. 
Formula Name Genus species or pharmaceutical nomenclature 
Tien Hsien Cordyceps sinensis, OldenLandia diffuse, Indigo pulverata, Polyporus umbellatus, Astragalus membranaceus, Panax ginseng, Solanum 
nigrum, Pogostemon cablin, Atractylodis macrocephalae, Trichosenthes kirilowii, Clematis chinensis, Margarita, Ligustrum 
lucidum, Glycyrrhiza uralensis, Ganoderma lucidium, Dioscorea batatas, Codonopsis pilosula, Lycium barbarum 
Unkei-to Ophiopogon japonicus, Pinellia ternata, Glycyrrhiza uralensis, Angelica acutiloba, Cnidium officinale, Paeonia suffruticosa, Evodia 
rutaecarpa, Zingiber officinale, Asini corii collas 
Vigconic Radix Ginseng, Cornu cervi, Cordyceps sinensis, Radix Salviae miltiorrhizae, Semen Allii, Fructus Cnidii, Fructus Evodiae, Rhizoma 
Kaempferiae 
Wheeze-relief-formula Fritillariae cirrhosae, Cordyceps sinensis, Astragalus mongholicus, Stemona sessilifolia, Scutellariae baicalensis 
Xia-Bai-San Morus alba, Lycium chinense, Glycyrrhiza glabra 
Xin-feng Astragalus membranaceus, Coix lacryma jobi, Scolopendra, Tripterygium wilfordii 
Yangyuk-Sanhwa-Tang Rehmanniae radix, Lonicera japonica, Forsythiae fructus, Gardeniae fructus, Menthae herba, Anemarrhena rhizome, gypsum 
fibrosum, Schizonepetae herba, Ledebouriellae radix 
Yi-fei Ruenn-hou Gycyrrhiza uralensis, Panax quinquefolis, Paeonia suffruticosa, Camellia sinensis 
Yuldahansotang Pueraria montana var. thomsonii, Astragalus membranaceus, Ligustici tenuissima, Raphani Satovi, Angelicae Dahuricae, Veratrum 
viride, Platycodon Grandiflora 
Zemaphyte Ledebouriella seseloides, Potentilla chinensis, Clematis armandii, Rehmannia glutinosa, Paeonia lactiflora, Lophatherum 
gracile, Dictamnus dasycarpus, Tribulus terrstris, Glycyrrhiza glabra, Schizonepeta tenuifolia 
Table 2A. In vivo. 
Formula name Preparation 
used 
Daily dose Duration of 
exposure 
Tissue Model Cytokines 
affected 
T helper 
influence 
Author/date 
Antitumor-I Capsule 800 mg/kg 8 days NK spleen 
Murine 
Tumor bearing IL-2↑,6↑ Th0 Lei and Chu 
(1996) 
Dang-gui-bu-xue-tang Aqueous 360 mg 7 days Lymphocytes 
Murine 
None IL-2↑ Th1 Chen (1994) 
Food Allergy Herbal 
Formula-1 
Aqueous 21 mg BID, 
Intragastric gavage 
7 weeks Splenocytes 
Murine 
Peanut allergen IL-4↓,5↓,13↓ Th1 Li et al. (2001) 
Food Allergy Herbal 
Formula-2 
Aqueous 20 mg BID, 
Intragastric gavage 
7 weeks Splenocytes 
Murine 
Peanut allergen IL4↓,5↓,13↓ 
IFN-γ↑ 
Th1 Srivastava et al. 
(2005) 
Hochuekki Aqueous 1000 mg/kg PO 2 days before to 4 
days after infection 
Bronchioles 
Murine 
Influenza IL-1α↓,6↓ 
GM-CSF 
Th0 Mori et al. 
(1999) 
Hochuekki Methanol 1000 mg/kg OD, 
Intragastric gavage 
2 days before to 2 
days after infection 
Bronchioles 
Murine 
Influenza aIFN-α↓↑ – Mori et al. 
(1999) 
Hochuekki Aqueous 1000 mg/kg QD, PO 7 days Spleen cells 
Murine 
OVA IL-4↓,5↑ 
IFN-γ↑ 
Th0 Ishimitsu et al. 
(2001) 
Hochuekki Aqueous 1000 mg/kg QD, PO 7 days Spleen and lung cells 
Murine 
OVA IL-4↓,5↑ – Ishimitsu et al. 
(2001) 
Hochuekki Aqueous 1000 mg/kg QD, PO 7 days Spleen cells 
Murine 
L. monocytogens IFN-γ↑ – Yamaoka et al. 
(2001) 
Hochuekki Aqueous 1000 mg/kg QD, PO 7 days Spleen cells 
Murine 
Anti CD24 
and/or anti CD3 
IFN-γ↑ – Yamaoka et al. 
(2001) 
Hochuekki Aqueous 1000 mg/kg QD, PO 21 days Gastric mucosa 
Murine 
H. pylori IFN-γ↑ – Yan et al. (2002) 
Hochuekki Aqueous 1000 mg/kg QD, PO 18 days Ear 
Murine 
Trinitro 
chlorobenzene 
IL-4↓ – Nakada et al. 
(2002) 
OVA: ovalbumin. 
aIFN-α was initially up-regulated and by the end of infection down-regulated as compared to the control group. 
 
Table 2B. In vivo. 
Formula name Preparation 
used 
Daily dose Duration of 
exposure 
Tissue Model Cytokines 
affected 
T helper 
influence 
Author/date 
Kakkon-to Aqueous 5.0 mg TID, PO 8 days Serum 
Murine 
Influenza IL-4↓  – Kurokawa et al. 
(2002) 
Keyuling Aqueous 0.18 mg/kg 30 days Serum 
Murine 
Radiation TNF↑ 
IL-18↑ 
– Jiang et al. (2004) 
Nao-yi-an Aqueous 4920 mg/kg 7 days Brain 
Murine 
Collagenase IL-6↑ – Xiao et al. (2002) 
Formula name Preparation 
used 
Daily dose Duration of 
exposure 
Tissue Model Cytokines 
affected 
T helper 
influence 
Author/date 
PG201 25% Ethanol 10 mg/mL QD, PO 18 days Ankle tissue 
Murine 
Rheumatoid 
Arthritis 
IL-1β↓ 
TNF-α↓ 
– Shin et al. (2003b) 
PG201 25% Ethanol 10 mg/mL QD, PO 18 days Serum 
Murine 
Rheumatoid 
Arthritis 
IL-4↑ – Shin et al. (2003b) 
Qing-huo-bai-du-yin Aqueous 4000 mg BID, PO 5 days Serum 
Murine 
Burn model IL-1β↓,4↑,6↓,10↑ Th2 Luo et al. (2004) 
Qing-huo-bai-du-yin Aqueous 4000 mg BID, PO 10 days Serum 
Murine 
Burn model IL-6↓,8↓,10↑ 
TNF↓ 
Th2 Luo et al. (2004) 
Qing-huo-bai-du-yin Aqueous 4000 mg BID, PO 20 days Serum 
Murine 
Burn model TNF↓ – Luo et al. (2004) 
Qingfu Guanjieshu 80% Ethanol 1940 mg/kg QD, PO 30 days Serum 
Murine 
Rheumatoid 
Arthritis 
IL-6↓ – Cai et al. (2005) 
Qingfu Guanjieshu 80% Ethanol 3890 mg/kg QD, PO 30 days Serum 
Murine 
Rheumatoid 
Arthritis 
IL-1β↓,6↓ 
TNF-α↓ 
– Cai et al. (2005) 
Shen-fu-tang Aqueous Unspecified IV 60 days T cell subtype 
Human 
Aplastic anemia IL-2↓ 
TNF↓ 
IFN-γ↓ 
Th2 Wang et al. (2005) 
Shi-ka-ron Aqueous 400 mg/kg QD, PO 5 days Spleen lymphocytes 
Murine 
Con A IL-2↑ 
IFN-γ↑ 
Th1 Jin and Kurashige 
(1996) 
Shi-ka-ron And 
cyclophosphamide 
Aqueous 300 mg/kg QD, PO 5 days Spleen lymphocytes 
Murine 
Con A IL-2↑ – Jin and Kurashige 
(1996) 
Shi-ka-ron And 
cyclophosphamide 
Aqueous 200 mg/kg QD, PO 5 days Spleen lymphocytes 
Murine 
Con A IFN-γ↑ – Jin and Kurashige 
(1996) 
Shin + Xiao + Xiang Powder 15,000 mg TID, PO 3 months Lymphocytes, 
Human 
PHA IL-4↑,5↓,10↑,13↓ – Yang et al. (2001) 
Shin + Xiao + Xiang Powder 15,000 mg TID, PO 3 months Mononuclear cells 
Human 
PHA IFN-γ↓ – Yang et al. (2001) 
Con A: concanavalin A, LPS: lipopolysaccharide, PHA: phytohemaggluttinin. 
 
Table 2C. In vivo. 
Formula name Preparation 
used 
Dose Duration of 
exposure 
Tissue Model Cytokines affected T helper 
influence 
Author/date 
Xia-Bai-San Aqueous 1 mg/kg PO 4 h Lung fluid 
Murine 
LPS IL-1β↓,6↓ 
TNF-α↓ 
– Yeh et al. (2006) 
Xia-Bai-San Aqueous 1 mg/kg PO 24 h Lung fluid 
Murine 
LPS IL-10↑ 
IL-10 (mRNA)↑ 
– Yeh et al. (2006) 
Xinfeng Capsule 4500 mg/day 3 months Serum 
Human 
Rheumatoid IL-10↑ 
TNF-α↓ 
Th2 Liu et al. (2006) 
Formula name Preparation 
used 
Dose Duration of 
exposure 
Tissue Model Cytokines affected T helper 
influence 
Author/date 
Yangkyuk-Sanhwa-Tang Aqueous 44,000 mg TID, PO 2 weeks Serum 
Murine 
Cerebral Infarct IL-2↓,4↓,6↓ 
TNF-α↓ 
IFN-γ↑ 
– Jeong et al. (2002) 
Yi-fey Ruenn-hou Aqueous 2 mg/mL QD, PO 6 months Serum 
Murine 
None IL-10↑ – Lin et al. (2004) 
Yi-fey Ruenn-hou Aqueous 8 mg/mL QD, PO 6 months Serum 
Murine 
None IL-4↑,10↑ Th2 Lin et al. (2004) 
Yi-fey Ruenn-hou Aqueous 40 mg/mL QD, PO 3 months Serum 
Murine 
None IL-4↑,10↑ 
IFN-γ↑ 
Th2 Lin et al. (2004) 
LPS: lipopolysaccharide. 
 
Table 3A. Ex vivo. 
Formula name Preparation used Dose Duration of 
exposure 
Cell type Inducing agent Cytokines affected Author/date 
Cathay 100 Tablet ground in 
food 
4 tablets/kg QD, PO 8 weeks Liver 
Murine 
Con A TNF-α↓ Batey and Cao 
(2000) 
Echinacea formula Capsule 6000 mg day 1, 
3000 mg × 9 days PO 
10 days Macrophages 
Human 
URI TNF↑ Barrett et al. 
(2002) 
Echinacea/Thuja 
Formula 
30% Ethanol 260 μL/kg QD, PO 3 days Spleen cells 
Murine 
LPS and Con A IL-2↑ 
IFN-γ↑ 
Bodinet et al. 
(2002) 
Echinacea/Thuja 
Formula 
30% Ethanol 260 μL/kg QD, PO 3 days Peritoneal 
macrophages 
LPS IL-1↑ 
TNF-α↑ 
Bodinet et al. 
(2002) 
Hachimi-jio-gan Aqueous 1000 mg/kg QD, PO 8 weeks Kidney cells 
Murine 
Anti-CD3 + anti-
CD28 antibody 
IL-4↑ 
IFN-γ↓ 
IL-12p35 (mRNA)↓ 
IL-12p40 (mRNA)↓ 
Furuya et al. 
(2001) 
Hachimi-jio-gan Aqueous 1000 mg/kg 5 
days/week PO 
4 weeks Spleen cells 
Murine 
Anti-CD40 IL-10↑,12p70↓ 
IL-12p35 (mRNA)↓ 
IL-12p40 (mRNA)↓ 
IL-18 (mRNA)↓ 
Furuya et al. 
(2002) 
Juzen-taiho-to Aqueous 1000 mg/kg QD, PO 2 weeks Spleen lypmphocytes 
Murine 
Con A IL-4↑,5↑ 
IFN-γ↑ 
Matsumoto and 
Yamada (2000) 
Juzen-taiho-to Aqueous 1000 mg/kg QD PO 2 weeks Gastric 
Lymphocytes 
Murine 
Con A IL-2↓,5↓,6↑ 
IFN-γ↑ 
Matsumoto and 
Yamada (2000) 
Kakkon-to Aqueous 5.0 mg TID, PO 8 days Bronchioles 
Murine 
Influenza IL-12↑ Kurokawa et al. 
(2002) 
Formula name Preparation used Dose Duration of 
exposure 
Cell type Inducing agent Cytokines affected Author/date 
Kanzo-bushi-to Aqueous 50 mg/kg PO QOD 48 h incubation 
of spleen and 
T6S cells 
T6S cells and spleen 
cell treated with 
herb 
Murine 
None IL-4↓ Kobayashi et al. 
(1994) 
Liu-Shen-Wan Powder 15 mg/kg PO 72 h Plasma 
Human 
Sepsis TNF-α↓ Ma et al. (2006) 
MSSM-002 Aqueous 360 mg/mL BID, PO 17 days Spleen cells 
Murine 
Allergies, Con A IL-4↓, 5↓,13↓ 
IFN-γ↑ 
Li et al. (2000) 
Con A: concanavalin A, LPS: lipopolysaccharide. 
 
 
Table 3B. Ex vivo. 
Formula name Preparation used Daily dose Duration of 
exposure 
Cell type Inducing agent Cytokines 
affected 
Author/date 
Ninjin-youei-to Aqueous 100 mg/kg IP 
injection 
1.5 and 3 h Serum and Peritoneal cavity 
Murine 
Unspecified IL-1↑,6↑ Yonekura et al. 
(1992) 
Ninjin-youei-to Aqueous 1000 mg/kg PO 6× 
a week 
24 weeks Spleen 
Murine 
Lupus IFN-γ↑ Zhou et al. 
(1994) 
Ninjin-youei-to + Prednisone Aqueous 1000 mg/kg PO 6× 
a week 
24 weeks Spleen 
Murine 
Lupus IL-2↑ 
IFN-γ↓ 
Zhou et al. 
(1994) 
Ninjin-youei-to Aqueous Unspecified 4 weeks C57BL/6 and BALB 
Splenocytes 
Murine 
Anti-CD3 IL-4↑ 
IFN-γ↑ 
Nakada et al. 
(2002) 
PanaWang Aqueous 12.2 mg/kg PO 7 days Splenocytes 
Murine 
ConA IFN-γ↑ Tega et al. 
(2005) 
Sairei-to Unspecified 7200 mg/kg QD, 
PO 
4 months Spleen cells 
Murine 
Con A Lupus IL-4↑ 
IFN-γ↓ 
Ito et al. (2002) 
Shin + Xiao + Xiang Powder 15,000 mg TID, PO 3 months Neutrophils 
Human 
Allergic rhinitis IL-8↑ Yang et al. 
(2002) 
Sho-saiko-to Aqueous 1000 mg/kg QD, 
PO 
3 weeks Lung 
Murine 
LPS IL-6↑ Ohtake et al. 
(2002) 
Sho-seryu-to 5% Aqueous gum 
acacia solution 
1000 mg/kg QD, 
PO 
28 days Spleen cells 
Murine 
OVA, CD4 
T cells, APC 
IL-4↓ 
IFN-γ↑ 
Ikeda et al. 
(2002) 
Echinacea purpurea, E. 
angustifolia, Thuja, Baptisia, 
30% Ethanol 260 μL/kg QD PO 3 days Spleen cells 
Murine 
LPS and Con A IL-2↑ 
IFN-γ↑ 
Bodinet et al. 
(2002) 
Echinacea purpurea, E. 
angustifolia, Thuja, Baptisia, 
30% Ethanol 260 μL/kg QD, PO 3 days Peritoneal macrophages 
Murine 
LPS IL-1↑ 
TNF-α↑ 
Bodinet et al. 
(2002) 
Formula name Preparation used Daily dose Duration of 
exposure 
Cell type Inducing agent Cytokines 
affected 
Author/date 
Xiao-chai-hu-tang Aqueous 1600 mg/kg QD, 
PO 
2 weeks Spleen and Liver cells 
Murine 
LPS TNF↑ Haranaka et al. 
(1985) 
Con A: concanavalin A, LPS: lipopolysaccharide, OVA: ovalbumin. 
 
Table 4A. In vitro. 
Formula name Preparation 
used 
Concentration Duration of 
exposure 
Cell type Inducing agent Cytokines 
affected 
Author/date 
Allergina Aqueous 10 μg/mL incubation 24 h T-cells 
Human 
None IL-4↑ 
IFN-γ↑ 
Jeong et al. (2003) 
Allergina Aqueous 100 μg/mL incubation 24 h T-cells 
Human 
None IL-2↑ Jeong et al. (2003) 
Allergina Aqueous 10 μg/mL incubation 24 h Peritoneal macrophages 
Murine 
None IL-12↑ 
TNF-α↑ 
Jeong et al. (2003) 
Allergina Aqueous 10 μg/mL incubation 24 h Peritoneal macrophages 
Murine 
IFN-γ TNF-α↑ Jeong et al. (2003) 
Allergina Aqueous 1000 μg/mL incubation 24 h Peritoneal macrophages 
Murine 
IFN-γ IL-12↑ Jeong et al. (2003) 
Allergina Aqueous 10 μg/mL incubation 24 h Peritoneal macrophages 
Murine 
IFN-γ + LPS TNF-α↓ Jeong et al. (2003) 
Bouum-Myunyuk-Dan Aqueous 100 μg/mL incubation 24 h T-cells 
Human 
None IL-2↑ 
IFN-γ↑ 
Jeong et al. (2004) 
Bouum-Myunyuk-Dan Aqueous 1000 μg/mL incubation 24 h T-cells 
Human 
None IL-4↑ 
IFNγ↓ 
Jeong et al. (2004) 
Bouum-Myunyuk-Dan Aqueous 10 μg/mL incubation 24 h Peritoneal macrophages 
Murine 
None IL-12↑ Jeong et al. (2004) 
Bouum-Myunyuk-Dan Aqueous 10 μg/mL incubation 24 h Peritoneal macrophages 
Murine 
IFN-γ IL-12↑ 
TNF-α↑ 
Jeong et al. (2004) 
Bouum-Myunyuk-Dan Aqueous 10 μg/mL incubation 24 h Peritoneal macrophages 
Murine 
IFN-γ + polymyxin B TNF-α↑ Jeong et al. (2004) 
LPS: lipopolysaccharide. 
 
Table 4B. In vitro. 
Formula name Preparation 
used 
Concentration Duration of 
exposure 
Cell type Inducing agent Cytokines 
affected 
Author/date 
Chizukit N Syrup 2 μL/mL incubation 24 h Monocytes 
Human 
None IL-1β↓,6↓,10↑ 
TNF-α↓ 
Barak et al. (2002) 
Formula name Preparation 
used 
Concentration Duration of 
exposure 
Cell type Inducing agent Cytokines 
affected 
Author/date 
CKBM Aqueous 20% incubation 18 h THP-1 monocytes 
Human 
None IL-10↑ 
IFN-γ↑ 
Chan et al. (2005) 
CKBM Aqueous 15% incubation 18 h THP-1 monocytes 
Human 
A23187 IL-1β↑ Chan et al. (2005) 
CKBM Aqueous 5% incubation 18 h THP-1 monocytes 
Human 
A23187 IFN-γ↑ Chan et al. (2005) 
CKBM Aqueous 20% incubation 18 h SupT1 and Ramos cells 
Human 
LPS IFN-γ↓ Chan et al. (2006) 
CPD 861 Aqueous 5000 μg/mL incubation 48 h HSC 
Murine 
None IL-6↓ You et al. (2001) 
Daeganghwal-tang Aqueous 100 μg/mL incubation 6 h Mast cells 
Murine 
PMA + A23187 IL-1β↓,6↓ 
TNF-α↓ 
Shin et al. (2003a) 
Fei-shu-ling Aqueous 50,000 μg/mL incubation 6 h Lung macrophage 
Murine 
LPS TNF↓ Zhang et al. (1999) 
Gamcho-Sasim-Tang Aqueous 1000 μg/mL incubation 24 h PBMC 
Human 
PHA IL-1β↓ 
IFN-γ↓, TNF-α↓ 
Kim et al. (2002b) 
A23187: Ca2+ionophore, LPS: lipopolysaccharide, PHA: phytohemaggluttinin, PMA: phorphol myristate. 
 
Table 4C. In vitro. 
Formula name Preparation 
used 
Concentration Duration of 
exposure 
Cell type Inducing agent Cytokines 
affected 
Author/date 
Herbkines Aqueous 10 μg/mL incubation 24 h T-cells 
Leukemic (MOLT-4) 
Human 
None IL-2↑ 
IFN-γ↑ 
Hong et al. (2005) 
Herbkines Aqueous 100 μg/mL incubation 24 h T-cells 
Leukemic (MOLT-4) 
Human 
None IL-4↑ Hong et al. (2005) 
Herbkines Aqueous 10 μg/mL incubation 24 h Peritoneal macrophage 
Murine 
IFN-γ IL-12↑ 
TNF-α↑ 
Hong et al. (2005) 
Herbkines Aqueous 10 μg/mL incubation 24 h Peritoneal macrophage 
Murine 
None IL-12↑ Hong et al. (2005) 
Hwanglyun-Haedok-Tang Aqueous 1000 μg/mL incubation 6 h Peritoneal mast cells 
Murine 
Anti DNP IgE 
Ab 
TNF-α↓ Kim et al. (1998) 
Immune System Formula Syrup 2 μL/mL incubation 24 h Monocytes 
Human 
None IL-1β↑,6↑,8↑,10↑ 
TNF-α↑ 
Barak et al. (2002) 
Jeo-Dang-Tang Aqueous 1000 μg/mL incubation 24 h Mononuclear cells 
Human 
None IL-4↑,10↑ 
TGF-β1 
Jeong et al. (2003) 
Formula name Preparation 
used 
Concentration Duration of 
exposure 
Cell type Inducing agent Cytokines 
affected 
Author/date 
Jeo-Dang-Tang Aqueous 100 μg/mL incubation 25 h Mononuclear cells 
Human 
PHA IL-4↓ Jeong et al. (2003) 
Jeo-Dang-Tang Aqueous 10 μg/mL incubation 25 h Mononuclear cells 
Human 
LPS IL-4↓,10↓ Jeong et al. (2003) 
Jeo-Dang-Tang Aqueous 1000 μg/mL incubation 25 h Mononuclear cells 
Human 
PHA IL-10↓ Jeong et al. (2003) 
Jeo-Dang-Tang Aqueous 1000 μg/mL incubation 25 h Mononuclear cells 
Human 
LPS TGF-β1↓ Jeong et al. (2003) 
Jeo-Dang-Tang Aqueous 100 μg/mL incubation 25 h Mononuclear cells 
Human 
PHA TGF-β1↓ Jeong et al. (2003) 
Anti DNP IgE Ab: anti dinitrophenol IgE antibody, LPS: lipopolysaccharide, PHA: phytohemaggluttinin. 
 
Table 4D. In vitro. 
Formula name Preparation 
used 
Concentration Duration of 
exposure 
Cell type Inducing agent Cytokines 
affected 
Author/date 
Kan jang Aqueous 14 μg/mL incubation 72 h Blood cells 
Human 
PHA TNF-α↑ Panossian et al. (2002) 
Kan jang Aqueous 35 μg/mL incubation 72 h Whole blood cells 
Human 
None IFN-γ↑ Panossian et al. (2002) 
Mao-Bushi-Saishin-to Aqueous 10 μg/mL incubation 2 and 7 days Peritoneal macrophages 
Murine 
Mycobacterium 
avium 
IL-10↓ Shimizu et al. (1999) 
Mao-Bushi-Saishin-to Aqueous 10 μg/mL incubation 4 weeks Lung cells 
Murine 
Mycobacterium 
avium 
TNF-α (mRNA)↓ 
IFN-γ (mRNA)↓ 
TGF-β (mRNA)↓ 
Shimizu et al. (1999) 
MSSM-002 Aqueous 50 μg/mL incubation 7 days T cells 
Human 
Allergies, 
conalbumin 
IL-4↓,5↓,13↓ Li et al. (2004) 
MSSM-002 Aqueous 1 μg/mL incubation Unspecified Spleen cells 
Murine 
Allergies, Con A IL-4↓,5↓ 
IFN-γ↑ 
Li et al. (2004) 
MSSM-002 Aqueous 50 μg/mL incubation Unspecified D10 cells 
Murine 
Allergies, Con A IL-4↓,5↓ Li et al. (2004) 
MSSM-002 Aqueous 1 μg/mL incubation 72 h Spleen cells 
Murine 
Conalbumin IL-4↓,5↓ Srivastava et al. (2004) 
MSSM-002 Aqueous 50 μg/mL incubation 72 h Spleen cells 
Murine 
Conalbumin IFN-γ↑ Srivastava et al. (2004) 
Protec Syrup 2 μL/mL incubation 24 h Monocytes 
Human 
None IL-1β↓,6↓,8↑,10↑ 
TNF-α↓ 
Barak et al. (2002) 
Con A: concanavalin A, PHA: phytohemaggluttinin.  
Table 4E. In vitro. 
Formula name Preparation 
used 
Concentration Duration of 
exposure 
Cell type Inducing agent Cytokines 
affected 
Author/date 
Sambucol Black Elderberry 
Syrup 
Syrup 2 μL/mL 
incubation 
24 h Monocytes 
Human 
None IL-1β↑,6↑,8↑ 
TNF-α↑ 
Barak et al. (2001) 
Sambucol Black Elderberry 
Syrup 
Syrup 2 μL/mL 
incubation 
24 h Monocytes 
Human 
None IL-1β↑,6↑,8↑,10↑ 
TNF-α↑ 
Barak et al. (2002) 
Sambucol for Kids Syrup 2 μL/mL 
incubation 
24 h Monocytes 
Human 
None IL-1β↑,6↑,8↑,10↑ 
TNF-α↑ 
Barak et al. (2002) 
Sesim-Tang Aqueous 10 μg/mL 
incubation 
18 h Astrocytes 
Murine 
LPS SP IL-1↓ 
TNF-α↓ 
Kim et al. (2002a) 
Shang Jong Shaur Tong Yong 
Tong Feng Wan 
50% Ethanol 250 μg/mL 
incubation 
48 h Mononuclear cells 
Human 
LPS IL-2↓ Chou and Chang 
(1998) 
Shaur Yau Gan Tsao Tang 50% Ethanol 100 μg/mL 
incubation 
48 h Mononuclear cells 
Human 
LPS IL-2↑ Chou and Chang 
(1998) 
Shi-bi-lin Aqueous 0.05 μg/mL 
incubation 
7 h HMC-1 
Mast cells 
Human 
PMA + A23187 IL-4↓,6↑,8↑ Zhao et al. (2005) 
Shi-bi-lin Aqueous 0.2 μg/mL 
incubation 
7 h HMC-1 
Mast cells 
Human 
PMA + A23187 IL-4↓,6↑ 
TNF↓ 
Zhao et al. (2005) 
Shi-ka-ron Aqueous 125 μg/mL 
incubation 
24 h Spleen lymphocytes 
Murine 
Con A IL-2↑ Jin and Kurashige 
(1996) 
Shi-ka-ron Aqueous 125 μg/mL 
incubation 
24 h Spleen lymphocytes 
Murine 
Con A IFN-γ↑ Jin and Kurashige 
(1996) 
Sho-saiko-to Aqueous 100 μg/mL 
incubation 
48 h Mononuclear cells, liver 
Human 
Hep C IL-10↑ Yamashiki et al. 
(1997) 
Shu Jin Lih An Saan 50% Ethanol 250 μg/mL 
incubation 
48 h Mononuclear cells 
Human 
LPS IL-2↓ Chou and Chang 
(1998) 
Tien Hsien Aqueous 1 μg/mL 5 days T-cells 
Whole blood 
Human 
PHA, TT, S. 
mutans, GftD 
IL-2↓,6↑,10↑ 
TNF-α↓ 
Sun et al. (2005) 
Unkei-to Aqueous 0.3 μg/mL 
incubation 
48 h Granulosa cells 
Human 
None IL-1β↑,8↑ Sun et al. (2004) 
Unkei-to Aqueous 3 μg/mL 
incubation 
48 h Granulosa cells 
Human 
None IL-6↑ Sun et al. (2004) 
A23187: Ca2+ionophore, Con A: concanavalin A, LPS: lipopolysaccharide, PHA: phytohemaggluttinin, PMA: phorphol myristate, SP: substance P. 
 
  
Table 4F. In vitro. 
Formula name Preparation 
used 
Concentration Duration of 
exposure 
Cell type Inducing agent Cytokines affected Author/date 
Vigconic Aqueous 100 μg/mL 
incubation 
20 h Lymphocytes 
Human 
None IL-8↑,10↑ Lee et al. (2006a) 
Vigconic Aqueous 1000 μg/mL 
incubation 
20 h Monocytes 
Human 
None IL-1β↑ Lee et al. (2006a) 
Vigconic Aqueous 400 μg/mL 
incubation 
20 h Monocytes 
Human 
None IL-8↑,10↑,12p70↑ Lee et al. (2006a) 
Vigconic Aqueous 100 μg/mL 
incubation 
24 h PBMC 
Human 
None mRNA: IL-1β↑ Pan-Hammarström 
et al. (2006) 
Vigconic Aqueous 100 μg/mL 
incubation 
48 h PBMC 
Human 
None mRNA: IL-1β↑,11,13↓ Pan-Hammarström 
et al. (2006) 
Vigconic Aqueous 100 μg/mL 
incubation 
24 h Spleen cells 
Human 
None mRNA: IL-1β↑,1α↑,4↑,6↑,8↑,19↑ 
IFN-γ ↑ 
Pan-Hammarström 
et al. (2006) 
Vigconic Aqueous 100 μg/mL 
incubation 
48 h Spleen cells 
Human 
None mRNA: IL-1β↑,1α↑,3↑,6↑,7↑,8↑ 
IL-12β2↓,12p35↓,12p40↑ 
IL-13↓,22↑ 
IFN-γ↑ 
Pan-Hammarström 
et al. (2006) 
Vigconic Aqueous 100 μg/mL 
incubation 
48 h Spleen cells 
Human 
Polymixin mRNA: IL-1α↑,6↑ 
IL-6↓(2nd donor) 
IFN-γ↑ 
Pan-Hammarström 
et al. (2006) 
Vigconic Aqueous 100 μg/mL 
incubation 
24 h Spleen cells 
Human 
Polymixin mRNA: IL-1α↑ 
IFN-γ↑ 
Pan-Hammarström 
et al. (2006) 
Wheeze-relief-formula Aqueous 1000 μg/mL 
incubation 
18 h Mononuclear cells 
Human 
Dermatophagoid 
espteronyssinus 
IL-5↓,10↓ 
TNF-α↓ 
Lee et al. (2006b) 
Yuldahansotang Aqueous 10 μg/mL 
incubation 
24 h Astrocytes 
Murine 
LPS SP IL-4↓ 
TNF-α↑ 
Choi et al. (2002) 
Yuldahansotang Aqueous 100 μg/mL 
incubation 
24 h Astrocytes 
Murine 
LPS SP IL-1↓,6↓ Choi et al. (2002) 
Zemaphyte Aqueous 0.1–100 μg/mL 
Best result not 
specified 
4 days, every 
other day 
Monocytes 
Human 
Atopic dermatitis IL-10↑ Novak et al. 
(2001) 
LPS: lipopolysaccharide, SP: substance P. 
3. Results 
 
Table 1A, Table 1B, Table 1C list the formula compositions. The majority of the studies utilized 
the well known Chinese formulas. In the case that the formula is used in traditional Japanese 
medicine the Japanese nomenclature of the formula is listed as well. Much of the phytotherapy in 
the Western countries includes TCM based formulas, which may explain why there appears to be 
less emphasis on the investigation of western herbal formulas. 
 
Much of the primary literature does not include a full listing of the Genus species of plants used, 
especially if they are listed in pharmaceutical notation which includes Genus and plant part used, 
but does not list plant species. Conversely, if the Genus species is listed, then the plant part used 
was commonly not listed. As a result of these omissions Table 1A, Table 1B, Table 1C lists 
either the Genus species or the pharmaceutical nomenclature as denoted in the reviewed study. 
 
Table 2A, Table 2B, Table 2C, Table 3A, Table 3B, Table 4A, Table 4B, Table 4C, Table 4D, 
Table 4E, Table 4F list, by formula, the results of the cytokines produced in response to 
formulas. Table 2A, Table 2B, Table 2C, Table 3A, Table 3B list the in vivo and ex vivo results 
respectively, while Table 4A, Table 4B, Table 4C, Table 4D, Table 4E, Table 4F list the in vitro 
work. The tables are partitioned into columns denoting the formula, type of 
preparation/extraction (aqueous, ethanolic, powder, etc.), concentration/dosage used, duration of 
exposure, the cell type, inducing agent and model (in vivo, ex vivo or in vitro). If one of these 
variables differed in an investigator's series of experiments, there are multiple listings of the 
same investigation to report the differing conditions in which an experiment was run. 
 
For the in vivo data tabulated in Table 2A, Table 2B, Table 2C there is also a column suggesting 
the effects on T helper (Th) cells. Although in some cases more data is needed to predict a Th1 
or Th2 biasing effect, with the information provided we have made a prelimary prediction of the 
direction (Th0, Th1 or Th2) of effect. This is based on the pattern of cytokine secretion that the 
formula showed in the in vivo models. In the following cases we declined to predict Th bias 
effects due to limited data; an effect on only one cytokine, an up or down-regulation on 
cytokines that have contradictory effects on Th cells, or cytokines whose effects have not been 
clearly elucidated in regard to Th effects. We also declined to make Th bias predictions on the ex 
vivo or in vitro models due to uncertainity in the accuracy of such models. 
 
The vast majority of herbal preparations used in this literature were aqueous extractions. Less 
frequently, ethanolic extractions were utilized. Rarely glucose or sucrose-based syrups were 
tested. For the in vivo investigations, aqueous extractions were the most common method of 
administration. Exceptions to this included powdered herb mixed into rat or mouse chow. 
 
The concentrations/dosages used varied considerably. For the in vitro work concentrations of 
extracts varied from 0.3 μg/mL to 1 g/mL. For the in vivo/ex vivo work the dosages ranged from 
0.18 mg/mL (murine) to 44 g (human). If there were 2 or more different concentrations used, for 
example in the case of demonstrating a dose dependent response, the lowest concentration that 
demonstrated a statistically significant effect is reported. Incubation times varied widely from 6 h 
to 4 weeks in the in vitro cell culture work and 1.5 h to 6 months in the in vivo/ex vivo work.  
 
The most common cell types utilized were splenoctyes, T cells, monocytes and macrophages and 
induction of these cells was clustered around a few stimulants: Con A, PHA and LPS. In some 
cases cytokines themselves were used as stimulants. In a number of investigations there were no 
inducers used and accordingly, this is notated as “none.” As seen by the listing of Table 4A, 
Table 4B, Table 4C, Table 4D, Table 4E, Table 4F the most common model type was in vitro 
work. If any of the above variables were altered in a group's experimental protocols, for instance 
if different inducers were tested, there is a separate listing for each variation of the model. 
 
The outcome of particular studies is listed under cytokines affected. The majority of 
investigations measured cytokine protein/peptide levels. However, a few groups measured 
transcriptional activity as well as protein levels. In these cases mRNA is listed to indicate that 
genes and not proteins were up or down regulated. 
 
4. Discussion 
 
 
Figure 1. Influences of IL-1 on human physiology (Th2 bias) (Illustrations by: Sariah Burns. 
Skeleton by: Microsoft Office Clipart. Endocrine System by: Merriam-Webster Inc.). 
 
Pharmacological therapy based on medicinal plants, such as the immunomodulators, is 
frequently based on combinations of herbs. Therefore, we reviewed the primary literature for 
formulas that demonstrate cytokine activity and listed the results in Table 2A, Table 2B, Table 
2C, Table 3A, Table 3B, Table 4A, Table 4B, Table 4C, Table 4D, Table 4E, Table 4F. The 
limitations of the data in this review are due to the use of in vitro assays for the majority of the 
investigations reviewed and animal models in the remaining investigations. Replicating 
physiologically relevant models of human physiology are difficult with in vitro methods 
(Freeman and Spelman, 2008). Cell culture conditions provide a markedly alien environment for 
cells. Genetic engineering generates cell lines that are stressed and incompletely understood. 
Therefore cultured cell lines response to experimental conditions should be carefully scrutinized. 
In addition, the absence of digestive and metabolic processing of complex extracts in vitro calls 
into question the significance of data gathered from such methodology. Further, concentrations 
utilized for in vitro models often do not correspond to physiologically relevant serum 
concentrations. For example, in the in vitro models investigating Allergina (Jeong et al., 2003) 
and Bouum-Myunyuk-Dan (Jeong et al., 2004) the researchers used up to 1 mg/mL, a 
concentration lacking physiological relevance (Fig. 1). 
 
Animal models also may misrepresent human physiology. Artificially generated pathology, 
confounding variables, differences in anatomy and biochemical pathways all call into question 
the validity of data gathered from animal models. Unfortunately, a previous review on herbs and 
cytokines found that most in vivo models are animal studies and that human studies are rare 
(Spelman et al., 2006a). 
 
Traditional use of medicinal plants can offer leads to their pharmacological activity. Seventy-five 
percent of new drugs made from natural products were “discovered” by following leads from 
traditional use of medicinal plants (Cott, 1995). For example, of 6350 proven antimicrobial 
species ∼63% have ethnobotanical documentation as antimicrobials (Mahady, 2005). Of the 90 
prescription drugs in use today in cancer treatment derived from plant species ∼74% of these 
were “discovered” by investigating traditional uses (Aggarwal et al., 2004). Hence, data from 
traditional use combined with outcomes from laboratory studies offers insights into possible 
modes of activity by the medicinal plants in question. The data in this review, combined with 
indications of traditional use, does offer insight into the effect of these herbal extracts on 
cytokine activity. Moreover, given the broad spectrum activity of cytokines, it is likely that at 
least some of the organ and tissue effects of these herbal remedies observed in traditional use are 
due, at least in part, to modulation of cytokine activity. 
 
The Th1/Th2 paradigm offers a useful perspective in viewing the many cytokine activities of the 
reviewed formulas. From this perspective, cytokines influence the balance between cell-mediated 
responses (Th1) and humoral immunity (Th2). Naïve T cells are activated to a Th0 cell, which 
show characteristics of both Th1 and Th2 cells, by numerous cytokines including IL-2, IL-4, IL-
5, IL-6, IL-10, IL-13, as well asTNF-α and IFN-γ. After differentiation cytokines which induce a 
cell-mediated response (IL-2, IL-3, IL-12, IFN-γ, TNF-α and TNF-β), shifting the immune 
response away from the humoral response, are known as Th1 cytokines (Fig. 2, Fig. 4, Fig. 5). 
Conversely, cytokines that shift the immune response towards humoral immunity (IL-4, IL-5, IL-
6, IL-10 and IL-13) and away from cell-mediated responses are considered Th2 cytokines (Fig. 
1, Fig. 3). Pharmacological agents that modulate the Th1 or a Th2 balance are therefore useful, 
depending on the state of the cellular milieu and the nature of any pathogens involved (e.g., 
intracellular parasites and viruses requiring a Th1 response, vs. extracellular microbes requiring 
Th2 response). Th2 cytokines are also important for immunity against cancer cells, but can 
contribute to pathology in allergy and various autoimmune disorders. 
 
 
Figure 2. Influences of IL-2 on human physiology (Th0 and Th1 bias) (Illustrations by: Sariah 
Burns). 
 
 
Figure 3. Influences of IL-6 on human physiology (Th0 and Th2 bias) (Illustrations by: Sariah 
Burns. Skeleton by: Microsoft Office Clipart. Endocrine System by: Merriam-Webster Inc.). 
 
From Table 2A, Table 2B, Table 2C it can be seen that not all formulas appear to have a 
cytokine stimulation pattern and as a result, are difficult to categorize in terms of Th1/Th2 
response. However, some formulas appear to down regulate Th2 response and others are 
reported to down regulate Th1 response. For example, “Food allergy formula I” (Table 2A) 
down regulates the Th2 cytokines IL-4, IL-5 and IL-13. As a result the immune response is 
shifted away from a Th2 response, resulting in a reduction in the allergic response. Similarly, 
Qing-huo-bai-du-yin, is shown in Table 2B to induce the Th2 cytokines (IL-4, IL-6, IL-10), 
which in the burn model utilized in these investigators model increases antibody production to 
fight the susceptibility to infection resulting from third degree burns (Luo, Zhou et al., 2004). In 
these examples, the constituents of the herbal formulation appear to induce a cytokine profile 
that “makes sense” in terms of the pharmacological applications of the formulas. 
 
 
Figure 4. Influences of IFN-γ on human physiology (Th0 and Th1 bias) (Illustrations by: Sariah 
Burns). 
 
As previously mentioned in regard to traditional use, the data can be extrapolated to aid in the 
understanding of traditional use of many of the reviewed formulas. For example, Sho-saiko-to, a 
traditional Japanese formula affecting cytokine activity, has undergone considerable research for 
immune and hepatic effects. This formula was found to repair “abnormalities in the cytokine 
cascades” and correct “deteriorated biological defense mechanisms”. Specifically, Sho-saiko-to 
increased depressed IL-10 levels found in hepatitis C patients, while decreasing elevated levels 
of IL-4 and IL-5 to normal levels (Yamashiki et al., 1997). A double-blind multi-center clinical 
trial of patients with chronic active hepatitis found Sho-saiko-to to lessen serum markers for liver 
injury (Hirayama et al., 1989). Other groups have found that Sho-saiko-to induces local IL-6 
stimulation in pulmonary tissue (Fig. 3). On fractionation of Sho-saiko-to, both a hydrophilic and 
a moderately hydrophobic fraction demonstrated IL-6 stimulation, suggesting that multiple 
constituents are responsible for the IL-6 activity (Ohtake et al., 2000). It may be that to repair 
“deteriorated biological defense mechanisms” multi-component therapeutics is advantageous; 
while certain phytochemicals may potentiate ADME properties, others may enhance 
pharmacodynamics (Eder and Mehnert, 1998, Spelman et al., 2006b). 
 
 
Figure 5. Influences of TNF-α on human physiology (Th0 and Th1) (Illustrations by: Sariah 
Burns. Endocrine System by: Merriam-Webster Inc.). 
 
Zuo et al. (2003), in a human study of the pharmacokinetics of key constituents in an herbal 
formula, found that the absorption of the constituents was delayed, their Cmax was higher and 
area under the curve was increased, compared to the same constituents if ingested as a single 
herb. They concluded that the concomitant constituents in the compound prescription increased 
efficiency and stability of the known active constituents. Of particular interest, human 
pharmacokinetic studies on Sho-saiko-to (containing Scutellaria baiclensis and Glycyrrhiza 
glabra) demonstrate efficient absorption of liquiritigenin and its glycoside liquiritin even though 
these constituents make up a mere 0.5% of this formula (Li et al., 1998). This suggests that 
absorption of these compounds may have been improved due to formulation (Zuo et al., 2003). 
 
Chronic diseases are increasingly being seen as multifactorial disorders (Cooper, 2003). 
Accordingly, multivalent pharmacology is progressively becoming a prerequisite in clinical 
medicine, whether for the treatment of infectious diseases, psychiatry, or cardiovascular 
disorders. Lansky and Von Hoff (2005) point out that even without full understanding of the 
pharmacology represented by complex pharmacological mixtures such as within medicinal 
plants, they may nonetheless have advantages. 
 
Intriguingly, medicinal plants are known to carry more than one active compound (Duke, 2007). 
Consequently the pharmacology associated with traditional remedies, especially formulas, is 
likely due to diverse modes of activity via various protein sites providing redundant and multiple 
pathway activity. Keith and Zimmermann (2004) suggest that many genes might need 
complementary action to modify disease processes. In other words, modulating a multiplicity of 
sites may be an asset in clinical therapeutics (Morphy et al., 2004). 
 
The partial perturbations of medicinal plants on a pharmacological network mimic physiological 
scenarios where hundreds of different enzyme systems and receptor types and subtypes act in 
concert (Ágoston et al., 2005). Recent research into cellular networks demonstrates that 
pharmacological agents that provide multiple signals can impact the complex equilibrium of 
whole cellular networks more favorably than drugs that act on a single target (Ágoston et al., 
2005, Briskin, 2000, Csermely, 2004, Csermely et al., 2005, Keith et al., 2005, Keith and 
Zimmermann, 2004, Morphy et al., 2004, Werner, 2003). Additionally, multi-target agents need 
affect their targets only partially, which corresponds well with the presumed low-affinity 
interactions of medicinal plants (Ágoston et al., 2005). Broader specificity, lower affinity, multi-
component compounds have been reported to be, in some cases, more efficient than high affinity, 
high specificity compounds (Csermely, 2004). This is compared to the complete elimination of a 
single network node (enzyme or receptor system), which is an unusual phenomenon not typically 
found in a physiological scenario (Csermely et al., 2005). Additionally, low-affinity, multi-target 
pharmacological strategies have demonstrated improved safety profiles (lower occurrence and 
reduced range of side-effects) than high affinity, single-target drugs (Csermely et al., 
2005, Lipton, 2004, Rogawski, 2000). 
 
Notably, although the majority of the studies did not include samples of single plants or known 
active constituents of plant species, those that did found that the active constituents or single 
plants, were not as effective as the tested herbal formulas (Ohtake et al., 2000, Pan-
Hammarström et al., 2006, Yamashiki et al., 1992). For example, when bicalin and glycyrrhizin, 
considered to have significant roles in the activity of S. baiclensis and G. glabra respectively, 
were tested alone they could not induce IL-10 secretion as these herbs did in formula. 
 
A further advantage of formulas is the reduction of adverse events by buffering toxicity that an 
herb or specific constituent may contain (Jia et al., 2004, Vickers and Zollman, 1999). For 
example, Aconitum carmichaeli, considered a powerful medicinal plant, is known as a low-dose 
botanical medicine due to the alkaloids aconitine, mesaconitine, and hypaconitine. At 
inappropriate doses these alkaloids can be toxic, but their metabolites are particularly effective 
antiiflammatories and antinociceptives (Hikino et al., 1980, Shu et al., 2006, Suzuki et al., 1994). 
Traditional practices include processes that are able to remove some, but not all, of the toxicity 
of Aconitum based medicine. The formula FAHF includes Aconitum. Li et al. (2001) reported 
that FAHF, at twice the therapeutic dose (42 mg/mouse) over 14 weeks, demonstrated no toxicity 
in a murine model. Additionally, the formula Mao-Bushi-Saishin-to, which contains Aconitum, 
did not demonstrate toxicity to mice or rats at a significant dose (100 mg/kg) for 13 weeks 
(Shimizu et al., 1999). Finally, QFGJS, also containing Aconitum, caused no mortality in a 
murine model at a single dose (33.6 g/kg) 346 times the suggested clinical dose for humans. 
Even after 3 months of dosing at 100 times the clinical dose, no obvious signs of toxicity have 
been reported (Cai et al., 2005). Kimura (2006) suggests that herbal formulations, as used in 
traditional systems of medicine, contain both yin and yang constituents that have mutually 
opposing pharmacological activities. Considering the toxicity of aconitine, mesaconitine, and 
hypaconitine from Aconitum, there may be “yin” principals opposing these “yang” alkaloids. 
Due to this paradoxical reversal of toxicity and the pharmacology complexity of multi-
component remedies, herbal formulas represent a particular methodological and technological 
challenge to study and thus, understand. 
 
Pharmacological research on the immunomodulators and, more broadly on medicinal plant 
formulas, is progressing as instrumental prowess and research methodology advance. 
Immunomodulators may offer a reasonable strategy for subtle induction of a variety of cytokines 
in immune-related diseases and other disorders. Moreover, research into these complex 
phytochemical cocktails may lead to further therapeutic advances and ultimately assist in 
elucidating the non-linear, non-additive interactions between the genome and proteome. 
 
5. Conclusion 
 
The current data on the influence of herbal formulas on cytokine activity is limited by the paucity 
of human studies. Despite the fact that the majority of the research listed in this review is in vitro 
or animal models, there does appear to be substantial historical, empirical, and increasing 
scientific evidence that herbal formulas may provide therapeutic application in the modulation of 
cytokines. Given the reported therapeutic success of these formulas by traditional cultures and 
modern clinicians, the activity of these medicinal plant mixtures may be partially due to their 
effects on cytokines, although other modes of activity are also likely. In addition, 
pharmacodynamic and pharmacokinetic potentiation of active constituents, as well as buffering 
of toxic constituents, appear to be common strategies of traditional formulas. It is our hope, the 
data collated and reviewed here will serve to stimulate further research on this topic. Further 
study of herbal mixtures on diseases and syndromes involving cytokines is necessary. 
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